EPTQ (Epitique) Dermal Filler Line — JETEMA ZEEP™ Technology — 1.1ml
- JETEMA ZEEP™ Technology — 24 mg/mL HA + 0.3% lido
- Three depth-tuned SKUs: S100, S300, S500
- CE 2292 certified, KFDA approved
- For licensed professionals only
| 1 - 4 boxes | $32.20 / box |
| 5 - 9 boxes | $30.91 / box |
| 10 - 19 boxes | $29.62 / box |
| 20+ boxes | $28.98 / box |
What Is EPTQ (Epitique) Dermal Filler Line — JETEMA ZEEP™ Technology — 1.1ml?
**EPTQ (Epitique)** is a three-variant Korean HA dermal filler series manufactured by JETEMA Co., Ltd., utilizing ZEEP™ purification technology to deliver 24 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine in three depth-tuned formulations (S100, S300, S500) spanning superficial dermis to deep subcutaneous correction for licensed professionals.
EPTQ (Epitique) shares JETEMA's ZEEP™ purification platform with Starfill, targeting ultra-low endotoxin levels (<0.1 EU/mL) and a modification degree (MoD) of approximately 1% for minimized residual BDDE. Three variants — S100, S300, and S500 — are differentiated by cross-linking density rather than HA concentration, offering precise depth matching from superficial dermal correction to deep subcutaneous volumization with results lasting up to 12 months.
Specifications
| Product name | EPTQ (Epitique) Dermal Filler Line — ZEEP™ Technology |
|---|---|
| Active ingredient | Cross-linked HA 24 mg/mL + Lidocaine 0.3% |
| Volume | 1 × 1.1ml pre-filled syringe + 2 × 27G needles |
| Modification degree | ~1% (MoD) |
| Cross-linker | BDDE (ZEEP process) |
| Application | Intradermal to subcutaneous per variant |
| Treatment areas | Fine lines, periorbital, neck, NLF, marionettes, lips, cheeks, chin, jawline, nose |
| Origin | South Korea (JETEMA Co., Ltd.) |
| Certification | CE 2292, KFDA, ISO 13485 |
| Storage | 2–25°C, do not freeze, protect from light |
| Shelf life | 24 months unopened |
Key Benefits
- ZEEP™ purification delivers ultra-low endotoxin (<0.1 EU/mL) with ~1% modification degree for minimized BDDE residue
- Three cross-linking densities (S100/S300/S500) match every dermal depth from superficial lines to subcutaneous volumization
- 24 mg/mL HA concentration with consistent backbone across all variants ensures predictable clinical outcomes
- CE 2292 and KFDA certified for regulatory confidence in professional practice
- Room-temperature stable storage (2–25°C) eliminates cold-chain logistics
Suggested Treatment Protocol
Treatment protocol varies by variant. EPTQ S100 is injected into the superficial-to-mid dermis for fine lines and periorbital area. EPTQ S300 targets the mid-to-deep dermis using a 27G needle for nasolabial folds, marionette lines, and lip body augmentation. EPTQ S500 is placed in the subcutaneous plane for cheek augmentation, chin projection, jawline contouring, and nose dorsum support. A full treatment plan of 1–3 sessions with 4–8 week intervals is recommended. The exact injection depth, volume, and treatment schedule should be determined by the treating practitioner based on individual patient anatomy and aesthetic goals.
Frequently Asked Questions
What is EPTQ (Epitique) Dermal Filler?
EPTQ (Epitique) is a three-variant monophasic HA dermal filler line delivering 24 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine. Using ZEEP™ purification technology, it achieves ultra-low endotoxin levels (<0.1 EU/mL) and a modification degree of approximately 1% for minimized residual BDDE. The range is depth-tuned into three formulations — S100, S300 and S500 — spanning superficial dermal correction to deep subcutaneous volumisation.
Which variant should I choose — S100, S300 or S500?
S100 targets the superficial-to-mid dermis for fine lines and the periorbital area. S300 is placed in the mid-to-deep dermis for nasolabial folds, marionette lines and lip body augmentation. S500 is injected into the subcutaneous plane for cheek augmentation, chin projection, jawline contouring and nose dorsum support. The treating practitioner should select the variant based on the target depth and treatment area.
How long do results last?
Results typically last up to 12 months, depending on the treatment area, injection depth, cross-linking density of the chosen variant and individual metabolism.
What is ZEEP™ technology?
ZEEP™ is a purification platform that delivers ultra-low endotoxin levels (<0.1 EU/mL) with a modification degree of approximately 1%, minimizing residual BDDE while preserving the natural properties of the HA gel.
How many sessions are typically needed?
A full treatment plan usually consists of 1–3 sessions at 4–8 week intervals. The exact number of sessions, injection depth and volume should be determined by the treating practitioner based on individual patient anatomy and aesthetic goals.
Is EPTQ safe and certified?
Yes — the filler line is CE 2292 certified and KFDA approved, and is manufactured under ISO 13485 quality systems.
How should it be stored?
Store at 2–25 °C, do not freeze and protect from light. The product is stable at room temperature, eliminating cold-chain logistics, and has a shelf life of 24 months unopened.
Can it be combined with other injectables?
Yes, it can be combined with other HA fillers, botulinum toxin or biostimulators in one session, respecting the recommended intervals between different products per each manufacturer's instructions.
Quality product that delivers as expected.
The 1.1ml syringe format is convenient for our clinic workflow. Less waste compared to the 1.5ml syringes we used to buy.
Decent product for the price point. Does what it's supposed to do.
Good value for the price. Our clinic has been satisfied with the results so far.
Please log in to leave a review.
